SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Nvidia is trending following a GTC keynote where CEO Jensen Huang projected over $1 trillion in AI infrastructure demand through 2027, signaling massive long-term growth for the company's Blackwell and Vera Rubin platforms. While the announcement fueled initial volatility and intense debate among investors over the stock's valuation and the reality of meeting such high revenue targets, the community remains divided between those viewing the pullback as a buying opportunity and others skeptical of the company's ability to sustain its premium market position.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJT is facing intense volatility as the community remains deeply divided over the current administration's handling of geopolitical tensions in the Strait of Hormuz, with active debate regarding potential military strategy, the effectiveness of international alliances, and the broader economic impacts of ongoing conflict. Investors are closely monitoring the company's price action as discussions shift between speculative trading and highly charged political discourse surrounding leadership and executive decision-making.

TMC the metals co., Inc. is a deep-sea minerals exploration company focused on the collection and processing of polymetallic nodules found on the seafloor in international waters of the Clarion Clipperton Zone in the Pacific Ocean (CCZ). These nodules contain high grades of four metals (nickel, copper, cobalt, manganese) which can be used as (i) feedstock for battery cathode precursors (nickel, cobalt and manganese sulfates, or intermediate nickel-copper-cobalt matte) for electric vehicles (EV) and renewable energy storage markets, (ii) copper cathode for EV wiring, energy transmission and other applications and (iii) manganese silicate for manganese alloy production required for steel production. The company was founded in 2021 and is headquartered in Vancouver, Canada.

TMC the metals company Inc

TMC is currently trending as investors react to the company's recent milestone of achieving 'substantial compliance' with U.S. regulatory standards for its seabed mining application, a development widely viewed as a major de-risking event. While the community remains divided between those navigating short-term volatility and others emphasizing long-term 'mineral independence' and government support, the conversation is heavily focused on the anticipated TMCR listing and the potential for accelerated permitting in the Clarion-Clipperton Zone.

Dogecoin is a cryptocurrency based on the popular "Doge" Internet meme and features a Shiba Inu on its logo. Dogecoin is a Litecoin fork. Introduced as a "joke currency" on 6 December 2013, Dogecoin quickly developed its own online community and reached a capitalization of US$60 million in January 2014. Compared with other cryptocurrencies, Dogecoin had a fast initial coin production schedule: 100 billion coins were in circulation by mid-2015, with an additional 5.256 billion coins every year thereafter. As of 30 June 2015, the 100 billionth Dogecoin had been mined.   Dogecoin was created by Billy Markus from Portland, Oregon and  Jackson Palmer from Sydney, Australia. Both wanted to create a fun cryptocurrency that will appeal beyond the core Bitcoin audience. Dogecoin is primarily used as a tipping system on Reddit and Twitter where users tip each other for creating or sharing good content. The community is very active in organising fundraising activities for deserving causes.  The developers of Dogecoin haven’t made any major changes to the coin since 2015. This means that Dogecoin could get left behind and is why Shibas are leaving Dogecoin to join more advanced platforms like Ethereum. One of Dogecoin strengths is its relaxed and fun-loving community. However, this is also a weakness because other currencies are way more professional.  To purchase Dogecoin, it involves downloading a crypto wallet, setting up a crypto exchange account and then trading away for your desired crypto currency. Once we have set up an account with a DOGE currency exchange and deposited some funds, you are ready to start trading.

Dogecoin

Dogecoin is capturing significant community attention as traders debate the potential impact of future X payment integration and its role in a broader digital monetary ecosystem. While some investors view current price consolidation as a strategic accumulation phase, others remain skeptical, fueling a polarized discussion between long-term proponents and those predicting further downside.

Electro Optic Systems Holdings Ltd. develops and produces products incorporating advanced electro-optic technologies for the aerospace market. It operates through the Space Systems and Defence Systems segments. The Space Systems segment is involved in ground products available to support the Australian and international space markets. The Defence Systems segment develops, manufactures, and markets advanced fire control, surveillance, and weapon systems to approved military customers. The company was founded by Benny Allan Greene in 1983 and is headquartered in Symonston, Australia.

Electro Optic Systems Holdings Ltd

Electro Optic Systems is gaining significant community attention as it secures multiple defense contracts for its counter-drone and laser weapon technologies, with investors highlighting the company's expanding backlog and strong performance in comparative military trials. The ongoing global demand for advanced, cost-effective air defense systems is driving discussions around the firm's strategic growth, international partnerships, and potential for increased market presence.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968, and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is currently trending as investors weigh conflicting signals from the Nvidia GTC conference and ongoing rumors regarding high-profile potential partnerships. While some community members remain focused on long-term foundry strategy and technical catalysts, the stock is seeing significant volatility driven by intense options activity and broader market sensitivities to geopolitical supply chain concerns.

Cingulate, Inc. operates as a clinical stage bio pharmaceutical company using a Precision Timed Release drug delivery platform technology to build a pipeline of next-generation pharmaceutical products. The firm initially focused on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD). It identifies and evaluates additional therapeutic areas, PTR technology employed to develop future product candidates. Cingulate was founded by Shane J. Schaffer, Craig Steven Gilgallon, Raul R. Silva, Matthew N. Brams in May 2012 and is headquartered in Kansas City, KS.

Cingulate Inc

Cingulate Inc. is generating significant market interest as investors position themselves ahead of the upcoming May 31 PDUFA date for its ADHD treatment, CTx-1301. Community sentiment is largely focused on the potential for upcoming patent approvals and the stock's low float, with many participants actively discussing the company's valuation potential and long-term commercialization prospects.

Ripple is the catchall name for the cryptocurrency platform, the transactional protocol for which is actually XRP, in the same fashion as Ethereum is the name for the platform that facilitates trades in Ether. Like other cryptocurrencies, Ripple is built atop the idea of a distributed ledger network which requires various parties to participate in validating transactions, rather than any singular centralized authority. That facilitates transactions all over the world, and transfer fees are far cheaper than the likes of bitcoin. Unlike other cryptocurrencies, XRP transfers are effectively immediate, requiring no typical confirmation time.  Ripple was originally founded by a single company, Ripple Labs, and continues to be backed by it, rather than the larger network of developers that continue bitcoin’s development. It also doesn’t have a fluctuating amount of its currency in existence. Where bitcoin has a continually growing pool with an eventual maximum, and Ethereum theoretically has no limit, Ripple was created with all of its 100 billion XRP tokens right out of the gate. That number is maintained with no mining and most of the tokens are owned and held by Ripple Labs itself — around 60 billion at the latest count.  Even at the recently reduced value of around half a dollar per XRP, that means Ripple Labs is currently sitting on around $20 billion worth of the cryptocurrency (note: Ripple’s price crashed hard recently, and may be worth far less than $60 billion by time you read this). It holds 55 billion XRP in an escrow account, which allows it to sell up to a billion per month if it so chooses in order to fund new projects and acquisitions. Selling such an amount would likely have a drastic effect on the cryptocurrency’s value, and isn’t something Ripple Labs plans to do anytime soon.  In actuality, Ripple Labs is looking to leverage the technology behind XRP to allow for faster banking transactions around the world. While Bitcoin and other cryptocurrencies are built on the idea of separating financial transactions from the financial organizations of traditional currencies, Ripple is almost the opposite in every sense.  XRP by Ripple price can be found on this page alongside the market capitalization and additional stats.

Ripple

Ripple (XRP) is experiencing high volatility as investors debate the legitimacy of recent price movements, with sentiment split between optimism over potential institutional adoption and skepticism regarding recurring sell-offs. The community remains deeply divided, with many actively trading around short-term price fluctuations while others hold long-term positions, waiting for clarity on regulatory milestones and market decoupling from Bitcoin.

USA Rare Earth, Inc. is domestic supplier of rare earth magnets and heavy rare earth elements. It is developing a vertically integrated, domestic supply chain for rare earth element magnet production, with a facility in Stillwater, Oklahoma, and mining rights to the Round Top heavy rare earth and critical minerals deposit in West Texas. The company was founded in May 2019 and is headquartered in Stillwater, OK.

USA Rare Earth Inc. - Ordinary Shares - Class A

USA Rare Earth Inc

USA Rare Earth Inc. is generating significant buzz as investors track its progress toward commercial production and vertical integration, with the community closely monitoring potential geopolitical impacts and government support for domestic critical mineral supply chains. The stock is currently marked by volatile price action, sparking intense debate among retail traders regarding its long-term potential as a key player in defense and semiconductor supply chains versus short-term manipulation.

Direxion Shares ETF Trust - Direxion Daily Homebuilders & Supplies Bull 3X ETF

Direxion Daily Homebuilders & Supplies Bull 3X Shares

Direxion Daily Homebuilders & Supplies Bull 3X Shares is currently trending as investors weigh conflicting catalysts, including recent interest rate volatility, stagnant housing affordability, and broader economic concerns. The community is actively debating the timing of a potential cyclical rebound, with many weighing the risks of volatility and decay in leveraged ETFs against the long-term potential of a housing market recovery driven by future monetary policy shifts.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>The study enrolled 20 high-risk patients with advanced, metastatic disease who had received one or more prior therapies.</li><li>The company said that the secondary endpoints included overall and progression-free survival.</li><li>Can-Fite announced exercise of certain outstanding warrants to purchase up to 795,869 ADS at a reduced price of $5 per share.&nbsp;</li></ul>Shares of Can-Fite BioPharma (CANF) surged more than 40% in pre-market trading on Wednesday after the company reported positive results from its Phase 2A open-label study of namodenoson in patients with advanced pancreatic ductal adenocarcinoma (PDAC) who had previously failed other treatments.The trial met its primary safety endpoint, showing that the drug was very well tolerated, with no new safety concerns observed. The study enrolled 20 high-risk patients with advanced, metastatic disease who had received one or more prior therapies.The company said that the secondary endpoints included overall and progression-free survival, with follow-up ongoing and one-third of patients still alive at data cut-off, as more mature results are expected to be presented at upcoming scientific meetings.Namodenoson is a selective A3 adenosine receptor agonist that has shown anti-tumor activity in preclinical models and is also being studied in advanced liver cancer. The drug has received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for the treatment of pancreatic cancer.<h2 class="st-heading-2">Exercising of Warrants for $4.0 Million Proceeds</h2>Can-Fite BioPharma also announced a definitive agreement for the immediate exercise of certain outstanding warrants to purchase up to 795,869 American Depositary Shares at a reduced price of $5 per share, down from $9.34. The transaction is expected to close around March 5, 2026.&nbsp;In connection with the cash exercise, the company will issue new unregistered warrants to purchase up to 1,591,738 ADSs at $5 per share, exercisable for 24 months.&nbsp;Can-Fite expects gross proceeds of about $4.0 million to support research, clinical trials, and general corporate purposes.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment for <a href="https://stocktwits.com/symbol/CANF">CANF</a> on Stocktwits turned 'extremely bullish' from 'bullish' a day earlier, amid 'extremely high' message volumes.<img src="https://news.stocktwits-cdn.com/CANF_jpg_27fa5e9013.webp" alt="CANF.jpg">One user said the company is a "great buyout candidate."<stembedurl>https://stocktwits.com/Pindis7/message/646561779</stembedurl>Year-to-date, the stock gained 63%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Why Did CANF Stock Soar 25% Today?

CANF company said its trial to study the treatment of patients with advanced pancreatic ductal adenocarcinoma met its primary endpoint.

Equity

The company said its trial to study the treatment of patients with advanced pancreatic ductal adenocarcinoma met its primary endpoint.

<ul class="summary-bullets"><li>The company said that the planned confirmation late-stage trial is designed to demonstrate the efficacy of Lacutamab in certain patients with Sézary syndrome and Mycosis fungoides.</li><li>The primary goal of the study is to gauge progression-free survival.&nbsp;</li><li>The FDA reviewed the protocol of the trial with no further comments, the company further noted.&nbsp; &nbsp;</li></ul>Shares of Innate Pharma SA (IPHA) soared 13% in the premarket session on Monday after the company said that the U.S. Food and Drug Administration had cleared a confirmatory late-stage trial of Lacutamab in cutaneous T-cell lymphomas to proceed.Cutaneous T-cell lymphoma (CTCL) is a rare type of non-Hodgkin lymphoma that affects the skin. Symptoms include patches, plaques, or tumors on the skin that can be itchy and may resemble eczema or psoriasis.<h2 class="st-heading-2">About the Late-Stage Confirmatory Trial</h2>The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.businesswire.com/news/home/20251109757297/en/Innate-Pharma-Announces-FDA-Clearance-to-Proceed-With-TELLOMAK-3-a-Confirmatory-Phase-3-Trial-of-Lacutamab-in-CTCL">said</a> that the planned confirmation late-stage trial is designed to demonstrate the efficacy of Lacutamab in patients with Sézary syndrome and Mycosis fungoides, who failed at least one prior line of systemic therapy. Both Sézary syndrome and Mycosis fungoides are types of cutaneous T-cell lymphomas.The primary goal of the study is to gauge progression-free survival or the length of time a patient lives with a disease, such as cancer, without it getting worse, which can include time when the cancer is stable or cured.The company now intends to initiate the confirmatory trial in the first half of 2026. The FDA reviewed the protocol of the trial with no further comments, the company further noted.In a mid-stage trial, Lacutamab demonstrated durable activity, a favorable safety profile, and improvements in patients’ quality of life.“...this milestone brings us one step closer to our next goal, submitting for accelerated approval in Sézary syndrome once the Phase 3 trial is underway,” CEO Jonathan Dickinson said.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/IPHA">IPHA stock</a> jumped from ‘neutral’ to ‘extremely bullish’ territory over the past 24 hours while message volume rose from ‘normal’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:623/63;" src="data:image/png;base64,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" width="623" height="63" alt="IPHA's Sentiment Meter and Message Volume as of 6:25 a.m. ET on Nov. 10, 2025 | Source: Stocktwits"><figcaption>IPHA's Sentiment Meter and Message Volume as of 6:25 a.m. ET on Nov. 10, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user recommended buying the stock under $3.<stembedurl>https://stocktwits.com/Iiii1ii/message/635561240</stembedurl>Another cheered the news as significant and positive.<stembedurl>https://stocktwits.com/StockNews_Live/message/635557846</stembedurl>IPHA stock is down by 4% this year and over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/us-lawmakers-reportedly-urge-ceo-to-end-union-busting-practices/cLPcLtxREcz">Starbucks Faces Political Heat: US Lawmakers Reportedly Urge CEO To End 'Union Busting’ Practices</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Rising stock market chart on a trading board background.

IPHA Stock Soars Pre-Market After FDA Clears Late-Stage Trial For Lacutamab In Rare Skin Cancers

Shares of Innate Pharma SA (IPHA) soared 13% in the premarket session on Monday after the company said that the U.S. Food and Drug Administration had cleared a confirmatory late-stage trial of Lacutamab in cutaneous T-cell lymphomas to proceed.

The company now intends to initiate the confirmatory trial in the first half of 2026.


Shares of Caribou Biosciences, Inc. (CRBU) jumped 52% in the pre-market session on Monday after the company announced positive data from early-stage trials of two of its CAR-T cell therapies.While one of the therapies was evaluated for the treatment of multiple myeloma, a blood cancer of plasma cells, the other was assessed in B-cell non-Hodgkin lymphoma (NHL), a cancer that originates in B lymphocytes, a type of white blood cell that fights infection.<h2 class="st-heading-2">Study In Multiple Myeloma</h2>The company said that the first clinical data for its CB-011 <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/11/03/3179047/0/en/Caribou-Biosciences-Announces-Positive-Data-from-CaMMouflage-Phase-1-Trial-of-CB-011-in-Multiple-Myeloma.html">highlights</a> its potential as a best-in-class allogeneic CAR-T cell therapy for relapsed or refractory multiple myeloma.The company now expects to advance the program into the dose expansion phase by the end of the year. In the dose escalation portion of the trial, CB-011 had a manageable safety profile across all dose levels, the company noted. The portion of the trial evaluated the safety and efficacy of CB-011 in 48 patients at multiple dose levels and following two different chemotherapy treatments.<h2 class="st-heading-2">Study In B-cell non-Hodgkin lymphoma</h2>Meanwhile, data from an early-stage trial of vispacabtagene regedleucel (Vispa-cel) demonstrated the efficacy and durability of the cell therapy in patients with relapsed or refractory B-cell non-Hodgkin lymphoma, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/11/03/3179104/0/en/Caribou-Biosciences-Announces-Positive-Data-from-ANTLER-Phase-1-Trial-Demonstrating-Efficacy-and-Durability-of-Vispa-cel-CB-010-an-Allogeneic-CAR-T-Cell-Therapy-on-Par-with-Autolog.html">said</a>. Vispa-cel was generally well-tolerated, allowing for administration in the outpatient setting, the company added.“We believe that with these results, Caribou has achieved what the field has long sought — strong evidence that an allogeneic CAR-T cell therapy can be on par with the efficacy and durability of autologous treatments and broaden access with a safety profile that allows for outpatient use,” said CEO Rachel Haurwitz.Allogeneic CAR-T cell therapy is a type of "off-the-shelf" cancer treatment that uses T-cells from a healthy donor, rather than the patient's own cells, allowing immediate availability. Autologous therapy, however, uses a patient's own cells or tissues, which are collected, processed outside the body, and then reintroduced to the same individual.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/CRBU">CRBU stock</a> stayed within the ‘bearish’ territory over the past 24 hours, while message volume stayed at ‘low’ levels.CRBU stock is up 52% this year and approximately 3% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/ford-sales-in-us-rise-1.6-percent-in-october/cL2NX8OR3CR">Ford Sales In US Rise 1.6% In October On Continued Truck Demand</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Caribou Biosciences Stock Soars Pre-market On Positive Early Trial Data For  Cancer Treatments

The company announced positive data from trials of CB-011 and Vispa-cel in relapsed or refractory multiple myeloma and B-cell non-Hodgkin lymphoma, respectively. 

Vor Bio (VOR) announced on Wednesday that its collaborator, RemeGen Co., achieved the primary goal in a late-stage study in China evaluating Telitacicept in adults with primary Sjögren's disease.Shares of <a href="https://stocktwits.com/symbol/VOR">VOR</a> jumped 19% in morning trade at the time of writing. On Stocktwits, retail sentiment around Vor Bio jumped from ‘bearish’ to ‘extremely bullish’ over the past 24 hours, while message volume rose from ‘extremely low’ to ‘high’ levels.<figure class="image"><img style="aspect-ratio:628/64;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_13_at_10_23_25_AM_png_ff26de0d0d.webp" alt="VOR's Sentiment Meter and Message Volume as of 10:23 a.m. ET on Aug. 13, 2025 | Source: Stocktwits" width="628" height="64"><figcaption>VOR's Sentiment Meter and Message Volume as of 10:23 a.m. ET on Aug. 13, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user expressed optimism about Vor, highlighting its ongoing trials and funding availability.<stembedurl>https://stocktwits.com/StockGuru95/message/624945818</stembedurl>Another said they are eyeing a breakout for the stock.<stembedurl>https://stocktwits.com/StockGuru95/message/624929413</stembedurl>The late-stage clinical study in China achieved the primary endpoint of improving disease activity measured by a reduction in EULAR Sjögren's syndrome disease activity index (ESSDAI), compared to placebo, the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.vorbio.com/news-releases/news-release-details/telitacicept-achieved-primary-endpoint-phase-3-clinical-study">said</a>. Telitacicept also demonstrated a favorable safety profile in the study, it added.RemeGen now plans to submit a Biologics License Application (BLA) to the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) in China for primary Sjögren’s disease. If approved, primary Sjögren’s disease will become Telitacicept’s fourth approved indication in China after systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and generalized myasthenia gravis (gMG), Vor Bio noted.Sjögren’s disease is a chronic autoimmune condition in which overactive B cells drive inflammation, damaging moisture-producing glands and, in many cases, other organs. Symptoms include dry eyes and dry mouth, alongside fatigue, pain, and systemic complications affecting the skin, lungs, kidneys, and nervous system.“Sjögren’s represents a significant global expansion opportunity for Vor beyond myasthenia gravis, further extending the reach and impact of our portfolio,” said Vor Bio CEO Jean-Paul Kress.Vor Bio and Remegen entered into an exclusive license agreement granting Vor Bio the global rights to develop and commercialize Telitacicept, excluding China, Hong Kong, Macau, and Taiwan, in June. On Wednesday, the company said that it is evaluating the timing of a global late-stage study of the drug in primary Sjögren's disease.VOR stock is up by 78% this year and by 138% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/cryptocurrency/virtuals-turns-agents-into-a-team/chrCLP7Rd9L">Virtuals Turns Agents Into A Team</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

Vor Bio Stock Jumped 19% Today And Retail Investors Are Eyeing A Breakout Rally: Here’s What’s Happening

A late-stage clinical study in China conducted by Vor Bio’s collaborator RemeGen Co., which is evaluating Telitacicept in adults with primary Sjögren's disease, achieved the primary endpoint of improving disease activity compared to placebo.

CNCR
Exchange Traded Concepts Trust - ETCT Loncar Cancer Immunotherapy ETF

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest CNCR News

CNCRExchange Traded Concepts Trust - ETCT Loncar Cancer Immunotherapy ETF